Zacks Investment Research·15h ago
TransMedics Completes PAD Aviation Investment to Expand in EuropeTMDX's PAD Aviation investment expands its OCS model into Europe, aiming to boost organ logistics, utilization and adoption.
TransMedics Group, Inc.(TMDX)Earnings, Financials & Key Ratios
TMDX•NASDAQ
$71.11
14.6× P/E·Price updated Jul 7, 2026
AboutTransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.Show more
- Revenue$605M+37.1%
- EBITDA$136M+137.1%
- Net Income$190M+436.6%
- EPS (Diluted)4.87+382.2%
- Gross Margin59.92%+0.9%
- EBITDA Margin22.42%+72.9%
- Operating Margin17.93%+111.2%
- Net Margin31.43%+291.3%
- ROE54.24%+179.7%
TMDX Price & Volume
TransMedics Group, Inc. (TMDX) stock price & volume — 10-year historical chart
Loading chart...
Logistics Scaling Pressures Impacting Operational Margin Stability
Investment Thesis • Updated 2026Q1
VerdictNeutral: While the company maintains a robust liquidity buffer with $461.7 million in cash
Growth:Decelerating
Profitability:Moderate
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Aviation operational cost volatility
Key Thesis Takeaways
- TransMedics is transitioning from hyper-growth to a more mature phase, evidenced by revenue growth decelerating to 21.2% in 2026Q1 from triple-digit levels in early 2024.
- While the company has successfully scaled its proprietary aviation logistics network, the shift toward an asset-heavy model has increased total debt to $818.8 million and introduced significant volatility in free cash flow.
- Investors should monitor whether the company can stabilize its operating margins, which compressed to 7.6% in 2026Q1, while managing the high capital intensity of its aviation fleet.
Verdict Logic
the inconsistent OCF/NI ratio of 3.35 in 2026Q1 and rising debt-to-equity ratio of 1.66 warrant a cautious approach until cash flow generation stabilizes.
TMDX Growth Metrics
TransMedics Group, Inc. (TMDX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years88.21%
3 Years86.42%
TTM30.24%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM251.23%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM221.32%
Return on Capital
10 Years-28.43%
5 Years-7.38%
3 Years3.88%
Last Year12.6%
TMDX Recent Earnings
TransMedics Group, Inc. (TMDX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.30-51.6%
$0.62
Rev
$174M-0.3%
$174M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.57+39.0%
$0.41
Rev
$161M+3.5%
$155M
Q4 2025
Oct 29, 2025Metric
Actual
Est
EPS
$0.66+78.4%
$0.37
Rev
$144M-7.5%
$155M
Q3 2025
Jul 30, 2025Metric
Actual
Est
EPS
$0.92+91.7%
$0.48
Rev
$157M+11.1%
$142M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.30vs $0.62-51.6% | $174Mvs $174M-0.3% |
| Q1 2026 | Feb 24, 2026 | $0.57vs $0.41+39.0% | $161Mvs $155M+3.5% |
| Q4 2025 | Oct 29, 2025 | $0.66vs $0.37+78.4% | $144Mvs $155M-7.5% |
| Q3 2025 | Jul 30, 2025 | $0.92vs $0.48+91.7% | $157Mvs $142M+11.1% |
Based on last 12 quarters of dataView full earnings history →
Latest TMDX News
Recent stock market news and headlines for TransMedics Group, Inc. (TMDX)
Seeking Alpha·21h ago
Strata Critical Medical: A Better Alternative To TransMedics In Organ Transplant LogisticsStrata Critical Medical is rated a buy, driven by expanding market share, operational efficiencies, and a comprehensive suite of transplant logistics and clinical services. SRTA's asset-light-to-moderate model, strategic acquisitions, and focus on NRP technology position it to benefit from industry consolidation and secular tailwinds. Gross margin improvement is a key near-term catalyst, with management incentivized to reach 25% margins by 2027; Q1 2026 gross margin reached 21%.
PRNewsWire·1 day ago
TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbHStrategic investment in Germany-based PAD Aviation, a premier European private aviation operator, lays the foundation for TransMedics to establish a dedicated organ transplantation air logistics network across Europe ANDOVER, Mass., July 6, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the closing of its strategic investment in PAD Aviation, a premier Germany-based private aviation operator.
The Motley Fool·4 days ago
Where Will TransMedics Group Stock Be in 10 Years?TransMedics is building more than a medical device business. Its Organ Care System and nationwide transplant logistics network create a difficult-to-replicate competitive advantage.
The Motley Fool·5 days ago
3 Growth Stocks to Buy on the DipInvesting in attractive stocks on the dip is a great way to earn above-average returns over the long run. The three stocks below have faced some challenges, but their prospects look fairly strong.
Peers Comparison
Key metrics vs top competitors for TransMedics Group, Inc. (TMDX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $71.12 | $2.46B | 14.60 | 37.13% | 31.43% | 54.24% | — | |
| $2.71 | $251.14M | -5.02 | — | — | -38.76% | — | |
| $18.34 | $5.01B | 32.75 | 3.21% | 11.75% | 9.63% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $83.58 | $4.59B | -18.78 | 10.74% | 7.47% | 9.13% | — | |
| $32.80 | $1.66B | -136.67 | 14.88% | -0.83% | -0.95% | — |
Compare TMDX vs Peers
TransMedics Group, Inc. (TMDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TMDX SEC Filings & Documents
TransMedics Group, Inc. (TMDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Feb 27, 2026·SEC
Material company update
Feb 24, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when TMDX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TMDX Frequently Asked Questions
TransMedics Group, Inc. (TMDX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is TransMedics Group, Inc.'s revenue?
TransMedics Group, Inc. (TMDX) reported $635.9M in revenue for fiscal year 2025. This represents a 10141% increase from $6.2M in 2016.
How fast is TransMedics Group, Inc. growing?
TransMedics Group, Inc. (TMDX) grew revenue by 37.1% over the past year. This is strong growth.
Is TMDX profitable?
Yes, TransMedics Group, Inc. (TMDX) is profitable, generating $171.9M in net income for fiscal year 2025 (31.4% net margin).
Dividend & Returns
What is TMDX's return on equity?
TransMedics Group, Inc. (TMDX) has a return on equity (ROE) of 54.2%. This is excellent, indicating efficient use of shareholder capital.
What is TransMedics Group, Inc.'s free cash flow?
TransMedics Group, Inc. (TMDX) generated $151.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.